Q-omics provides the consensus-scored MEMO1 profile across patient tissues and cancer cell-line models. MEMO1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MEMO1 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, MEMO1 protein abundance shows 21,104 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight ACC, HNSC, and PDAC as cancer lineages where MEMO1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MEMO1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MEMO1 survival associations across molecular data types. MEMO1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (5) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MEMO1 RNA expression–survival associations across cancer types. High MEMO1 expression shows unfavorable associations in ACC, LIHC, CESC, KIRC, UCEC and KIRP. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MEMO1 RNA expression.
This table summarizes MEMO1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for MEMO1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MEMO1 shows higher tumor expression in HNSC, BLCA, LUSC, LUAD, LIHC and COAD. The HNSC box plot shows higher MEMO1 RNA expression in tumor versus normal tissue (log2 FC = +0.387, t-test p < 0.001).
This table shows molecular features associated with MEMO1 in patient tissues and cancer cell lines. In patient samples, MEMO1 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, MEMO1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BREAST.
